Artwork

Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D

5:51
 
Share
 

Manage episode 414022686 series 2908385
Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

(00:32)
Could you provide us with a little bit of information about yourself and your background?

(01:18)
Can you start with a brief overview of the assay?

(02:13)
Which patients should have this testing and when should it be performed?

(03:21)
Are there alternative test options available and how do those compare with the folate receptor alpha assay?

(03:57)
How are the results used in patient care?

  continue reading

308 episodes

Artwork
iconShare
 
Manage episode 414022686 series 2908385
Content provided by Mayo Clinic Laboratories. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Mayo Clinic Laboratories or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.

(00:32)
Could you provide us with a little bit of information about yourself and your background?

(01:18)
Can you start with a brief overview of the assay?

(02:13)
Which patients should have this testing and when should it be performed?

(03:21)
Are there alternative test options available and how do those compare with the folate receptor alpha assay?

(03:57)
How are the results used in patient care?

  continue reading

308 episodes

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide